Sell Suven Pharmaceuticals; target of Rs 571: Geojit
Geojit is bearish on Suven Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 571 in its research report dated February 29, 2024.
Read MoreGeojit is bearish on Suven Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 571 in its research report dated February 29, 2024.
Read MoreThe Rollover for the Nifty Index futures stood at 79.31 percent, a decline from the previous month#39;s 81.28 percent and the three-month average of 80.04 percent
Read MoreSharekhan is bullish on State Bank of India has recommended buy rating on the stock with a target price of Rs 915 in its research report dated February 29, 2024.
Read MoreThe origin stories of Huawei and Comac are similar. Although the former is not state-owned, both benefit from serving explicit national interests, alleged technology theft, and continuously securing local orders at the expense of arguably superior foreign alternatives. Yet Huawei’s…
Read MoreThe origin stories of Huawei and Comac are similar. Although the former is not state-owned, both benefit from serving explicit national interests, alleged technology theft, and continuously securing local orders at the expense of arguably superior foreign alternatives. Yet Huawei’s…
Read MoreThe NSE and BSE will on March 2 conduct a special trading session to evaluate the readiness of market infrastructure institutions to handle unforeseen events such as system outages
Read More